USANA HEALTH SCIENCES INC (USNA) — SEC Filings

Latest SEC filings for USANA HEALTH SCIENCES INC (USNA), explained in plain English.

Sentiment Overview: 2 bearish, 28 neutral

Recent Filings (30)

• USANA Swings to Q3 Loss Amid Soaring Costs, Sales Up 6.7% — 10-Q · 2025-11-05T00:00:00.000Z [bearish] Risk: high
  USANA Health Sciences Inc. reported a significant net loss of $6.522 million for the three months ended September 27, 2025, a sharp decline from net earnings of
• USANA Health Sciences Files 8-K on Financials — 8-K · 2025-10-22T00:00:00.000Z [neutral] Risk: low
  USANA Health Sciences, Inc. filed an 8-K on October 22, 2025, reporting on its results of operations and financial condition. The filing also included Regulatio
• USANA Health Sciences Files 8-K on Financials — 8-K · 2025-10-09T00:00:00.000Z [neutral] Risk: low
  USANA Health Sciences, Inc. filed an 8-K on October 9, 2025, reporting on its results of operations and financial condition. The filing also includes Regulation
• USANA Q2 Revenue Plunges 15.4% Amidst Global Headwinds — 10-Q · 2025-08-05T00:00:00.000Z [bearish] Risk: high
  USANA Health Sciences Inc. reported a significant decline in revenue for the second quarter ended June 28, 2025, falling to $210.5 million from $248.6 million i
• USANA Health Sciences Files 8-K on Financials — 8-K · 2025-07-22T00:00:00.000Z [neutral] Risk: low
  On July 22, 2025, USANA Health Sciences, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, al
• USANA Health Sciences Enters Material Agreement, Creates Financial Obligation — 8-K · 2025-07-01T00:00:00.000Z [neutral] Risk: medium
  On June 27, 2025, USANA Health Sciences, Inc. entered into a material definitive agreement, likely related to financing or a significant operational change. Thi
• USANA Health Sciences Announces Director Changes and Executive Compensation — 8-K · 2025-05-20T00:00:00.000Z [neutral] Risk: medium
  On May 19, 2025, USANA Health Sciences, Inc. filed an 8-K report detailing several key events. The company announced the departure of Director David L. Hood and
• USANA Health Sciences Files Q1 2025 10-Q — 10-Q · 2025-05-06T00:00:00.000Z [neutral] Risk: low
  USANA Health Sciences Inc. filed its 10-Q for the period ending March 29, 2025. The filing provides financial data for the first quarter of 2025, comparing it t
• USANA Health Sciences Executive Compensation Filing — DEFA14A · 2025-05-01T00:00:00.000Z [neutral] Risk: low
  USANA Health Sciences Inc. filed a DEFA14A on May 1, 2025, detailing executive compensation and related matters for the fiscal year ending December 28, 2024. Th
• USANA Health Sciences Files 8-K on Financials — 8-K · 2025-04-22T00:00:00.000Z [neutral] Risk: low
  On April 22, 2025, USANA Health Sciences, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, a
• USANA Health Sciences DEFA14A: Executive Compensation Details — DEFA14A · 2025-04-16T00:00:00.000Z [neutral] Risk: low
  USANA Health Sciences Inc. filed a DEFA14A on April 16, 2025, detailing executive compensation and related matters for the fiscal year ending December 28, 2024.
• USANA Health Sciences Files Definitive Proxy Statement — DEFA14A · 2025-04-09T00:00:00.000Z [neutral] Risk: low
  USANA Health Sciences, Inc. filed a Definitive Proxy Statement (DEFA14A) on April 9, 2025. This filing is related to the company's proxy materials, which are ty
• USANA Health Sciences Executive Compensation Filing — DEF 14A · 2025-04-04T00:00:00.000Z [neutral] Risk: medium
  USANA Health Sciences Inc. filed a DEF 14A on April 4, 2025, detailing executive compensation for the fiscal year ending December 28, 2024. The filing includes
• USANA Health Sciences Files 2024 10-K — 10-K · 2025-03-12T00:00:00.000Z [neutral] Risk: medium
  USANA Health Sciences Inc. filed its 2024 10-K on March 12, 2025, reporting on its fiscal year ending December 28, 2024. The company, based in Salt Lake City, U
• USANA Health Sciences Files 8-K/A Amendment — 8-K/A · 2025-03-07T00:00:00.000Z [neutral] Risk: low
  USANA Health Sciences, Inc. filed an 8-K/A on March 7, 2025, to amend its previous filing. The amendment pertains to financial statements and exhibits related t
• USANA Health Sciences Files 8-K on Financials — 8-K · 2025-02-25T00:00:00.000Z [neutral] Risk: low
  USANA Health Sciences, Inc. filed an 8-K on February 25, 2025, to report on its results of operations and financial condition. The filing also includes informat
• USANA Health Sciences Acquired byెంట్‌ for $7.30/Share — 8-K · 2024-12-23T00:00:00.000Z [neutral] Risk: low
  On December 23, 2024, USANA Health Sciences, Inc. announced the completion of its acquisition by an affiliate ofెంట్‌, a global investment firm. The transaction
• USANA Health Sciences Files Q3 2024 10-Q — 10-Q · 2024-11-05T00:00:00.000Z [neutral] Risk: medium
  USANA Health Sciences Inc. reported its third-quarter results for the period ending September 28, 2024. The company's filing indicates financial data and operat
• USANA Health Sciences Files 8-K on Financials — 8-K · 2024-10-22T00:00:00.000Z [neutral] Risk: low
  On October 22, 2024, USANA Health Sciences, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition,
• USANA Health Sciences Files Q2 2024 10-Q — 10-Q · 2024-08-06T00:00:00.000Z [neutral] Risk: medium
  USANA Health Sciences Inc. filed its 10-Q for the period ending June 29, 2024. The filing details financial performance and operational updates for the second q
• USANA Health Sciences Files 8-K Report — 8-K · 2024-07-23T00:00:00.000Z [neutral] Risk: low
  On July 23, 2024, USANA Health Sciences, Inc. filed an 8-K report detailing its financial results and other relevant information. The filing includes informatio
• USANA Health Sciences Files 10-Q for Q1 2024 — 10-Q · 2024-05-07T00:00:00.000Z [neutral] Risk: low
  USANA Health Sciences Inc. filed its 10-Q for the period ending March 30, 2024. The company, incorporated in Utah, operates in the medicinal chemicals and botan
• USANA Health Sciences Files 8-K on Financials — 8-K · 2024-04-30T00:00:00.000Z [neutral] Risk: low
  On April 30, 2024, USANA Health Sciences, Inc. filed an 8-K report detailing its financial results and other relevant information. The filing includes financial
• USANA Health Sciences Files Proxy Materials — DEFA14A · 2024-03-27T00:00:00.000Z [neutral] Risk: low
  USANA Health Sciences, Inc. filed a Definitive Additional Materials (DEFA14A) on March 27, 2024. This filing is related to their proxy statement and indicates n
• USANA Health Sciences DEF 14A: Executive Compensation Details — DEF 14A · 2024-03-22T00:00:00.000Z [neutral] Risk: low
  USANA Health Sciences Inc. filed its DEF 14A on March 22, 2024, detailing executive compensation for the fiscal year ending December 30, 2023. The filing includ
• USANA Health Sciences Files 2023 10-K Report — 10-K · 2024-02-27T00:00:00.000Z [neutral] Risk: medium
  USANA HEALTH SCIENCES INC filed its 10-K report on February 27, 2024, for the fiscal year ended December 30, 2023. The filing confirms the company's operations
• Vanguard Trims USANA Health Sciences Stake to 5.7% — SC 13G/A · 2024-02-13T00:00:00.000Z [neutral] Risk: low
  The Vanguard Group, a major investment firm, filed an amended SC 13G/A on February 13, 2024, disclosing its ownership in USANA Health Sciences Inc. As of Decemb
• Renaissance Tech Amends USANA Health Sciences Stake — SC 13G/A · 2024-02-13T00:00:00.000Z [neutral] Risk: low
  Renaissance Technologies LLC, a major investment firm, filed an amendment to their SC 13G, indicating their ownership in USANA Health Sciences Inc. as of Decemb
• USANA Health Sciences Files 8-K on Financial Condition & Operations — 8-K · 2024-02-06T00:00:00.000Z [neutral]
  USANA Health Sciences, Inc. filed an 8-K on February 6, 2024, to report on its results of operations and financial condition, as well as to make a Regulation FD
• BlackRock Amends USANA Health Sciences Stake as of Dec 31, 2023 — SC 13G/A · 2024-01-24T00:00:00.000Z [neutral]
  BlackRock Inc. filed an amended Schedule 13G/A on January 24, 2024, indicating a change in its ownership stake in USANA Health Sciences Inc. as of December 31,